Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 598
- Registration Number
- NCT00661102
ADVANCE Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) + Adefovir Dipivoxil in Patients With Hbe(-) Chronic Hepatitis B
Phase 3
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: peginterferon alfa-2a [Pegasys]
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 10
- Registration Number
- NCT00661076
A Study of Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Predialysis Patients Not Treated With ESA.
Phase 3
Completed
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2016-08-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 75
- Registration Number
- NCT00661388
A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 132
- Registration Number
- NCT00661505
- Locations
- 🇹🇷
Adnan Menderes Uni School of Medicine; Physical Therapy & Rehabilitation, Aydin, Turkey
🇹🇷Trakya University Medical Faculty; Internal Medicine; Nephrology, Edirne, Turkey
🇹🇷Izmir Ataturk Research and Training Hospital; The Clinic of Nephrology, Izmir, Turkey
A Study of Avastin (Bevacizumab) in Combination With Docetaxel and Cisplatin in Patients With Metastatic or Locally Advanced Non-small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2014-07-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT00661778
A Study of Intravenous Mircera in Participants With Chronic Renal Anemia Who Are on Dialysis
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2016-03-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 124
- Registration Number
- NCT00660023
A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome
Phase 3
Completed
- Conditions
- Coronary Heart Disease
- Interventions
- Drug: Evidence-based medical care for Acute Coronary SyndromeDrug: Placebo
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2020-01-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 15871
- Registration Number
- NCT00658515
A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients
- First Posted Date
- 2008-04-10
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 476
- Registration Number
- NCT00655538
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
Phase 2
Completed
- Conditions
- Coronary Heart Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-04-10
- Last Posted Date
- 2020-01-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 130
- Registration Number
- NCT00655473
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Phase 2
Completed
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2015-02-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 467
- Registration Number
- NCT00652366
© Copyright 2025. All Rights Reserved by MedPath